Inquérito de toxoplasmose e de tripanossomíases realizado no Território do Amapá pela III Bandeira Científica do Centro Acadêmico "Oswaldo Cruz" da Faculdade de Medicina da Universidade de São Paulo

The survey was performed in three localities, in January 1962, and included inhabitants with 10 or more years of age and who had never left the Amazon Region.The Sabin-Feldman dye test was positive in 68.1 percent of 354 persons examined and the intradermal test with toxoplasmin in 46.4 percent of 366. The distribution of positive tests by locality, age, sex and race are presented.Through the complement fixation test for Chagas' disease (Guerreiro and Machado's test) performed in 353 persons and the xenodiagnosis in 116, no evidence of trypanosome infection was found.A severe malária outbreak which was occurring in the region is discussed.Descreve-se uma excursão realizada em janeiro de 1962 por estudantes da Faculdade de Medicina da Universidade de São Paulo ao Território do Amapá, onde realizaram inquéritos de toxoplasmose e tripanossomíase na cidade de Macapá e nas vilas de Paredão e Ferreira Gomes.A reação de Sabin-Feldman foi positiva em 68,1 % das 354 pessoas examinadas e a intradermorreação com toxoplasmina em 46,4% de 366. A distribuição das provas positivas é apresentada por localidade, sexo, idade e côr.A reação de fixação do complemento para doença de Chagas (prova de Guerreiro e Machado, técnica quantitativa), feita em 353 pessoas, não apresentou nenhum resultado seguramente positivo, sendo ainda negativos os 116 xenodiagnósticos efetuados com ninfas de triatomíneos (Rhodnius prolixus).Fazem-se ainda considerações sobre o intenso surto de malária que ocorria então na região

Evaluation Of Tolerability Of Enteric-coated Mycophenolate Sodium Versus Mycophenolate Mofetil In De Novo Renal Transplantation.

Mycophenolate mofetil (MMF), pro-drug mycophenolic acid (MPA) is an immunosuppressive effective in the prophylaxis of acute rejection, but associated with gastrointestinal adverse events. Mycophenolate sodium (MPS) with enteric coating was developed with intention of reducing such gastrointestinal adverse events associated with MPA. To evaluate the tolerability of EC-MPS and MMF in renal transplant recipients. Retrospective, multicenter study, included 1380 patients who underwent a transplant between 07/01/2004 and 31/07/2007 in 18 Brazilian centers.Results1380 patients enrolled, 702 received EC-MPS and 678 received MMF. The average age of patients was 42.3 years, 60% were male and 62.5% of Caucasian ethnicity. The incidence of events evaluated in the composite endpoint of efficacy was not different between groups at the end of 24 months follow-up (22.9% for EC-MPS to MMF versus19.9%, p = 0.203). Patients treated with EC-MPS had a higher incidence of gastrointestinal adverse events compared to those treated with MMF (57.7%vs. 52.5%), but there was no statistical difference between groups. Viral infections were more frequent in the EC-MPS group (38.2%) compared with MMF (32.6%). There was no difference in mean tolerated dose after the first (1187 ± 344vs. 1209 ± 426 mg, p = 0.294) and second year (1172.3 ± 347 mgvs. 1197.4 ± 430.6 mg, p = 0.241) after transplantation. There was no statistical difference in the incidence of acute rejection, delayed graft function and gastrointestinal events among treatments. The average tolerated dose of MPA was similar between groups; however, patients treated with MMF underwent more dose reductions and discontinuations of treatment.37291-29